Trial Profile
Atorvastatin therapy for the prevention of atrial fibrillation (SToP-AF)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms SToP-AF
- 01 Apr 2011 Results published in the Journal of Cardiovascular Electrophysiology.
- 01 Sep 2010 Results have been presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 03 Nov 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.